pI: 6.8202 |
Length (AA): 492 |
MW (Da): 53869 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
2 | 491 | 1zk7 (A) | 1 | 466 | 23.00 | 0 | 1 | 1.1 | -0.25 |
3 | 487 | 1aog (A) | 3 | 487 | 99.00 | 0 | 1 | 2.23 | -1.59 |
2 | 488 | 2wpf (A) | 1 | 488 | 82.00 | 0 | 1 | 1.96014 | -0.9 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Ortholog group members (OG5_126785)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G54660 | glutathione reductase |
Arabidopsis thaliana | AT3G24170 | glutathione-disulfide reductase |
Babesia bovis | BBOV_I002190 | thiodoxin reductase, putative |
Brugia malayi | Bm1_04825 | glutathione reductase |
Brugia malayi | Bm1_36410 | Thioredoxin reductase |
Candida albicans | CaO19.11623 | similar to S. cerevisiae GLR1 (YPL091W) glutathione oxidoreductase |
Candida albicans | CaO19.4147 | similar to S. cerevisiae GLR1 (YPL091W) glutathione oxidoreductase |
Caenorhabditis elegans | CELE_C46F11.2 | Protein GSR-1, isoform B |
Caenorhabditis elegans | CELE_ZK637.10 | Protein TRXR-2 |
Cryptosporidium hominis | Chro.20464 | thioredoxin reductase |
Cryptosporidium parvum | cgd2_4320 | thioredoxin reductase 1 |
Dictyostelium discoideum | DDB_G0272754 | glutathione reductase |
Drosophila melanogaster | Dmel_CG11401 | thioredoxin reductase 2 |
Drosophila melanogaster | Dmel_CG2151 | Thioredoxin reductase-1 |
Escherichia coli | b3500 | glutathione oxidoreductase |
Echinococcus granulosus | EgrG_000222300 | thioredoxin glutathione reductase |
Echinococcus multilocularis | EmuJ_000222300 | thioredoxin glutathione reductase |
Homo sapiens | ENSG00000197763 | thioredoxin reductase 3 |
Homo sapiens | ENSG00000104687 | glutathione reductase |
Homo sapiens | ENSG00000198431 | thioredoxin reductase 1 |
Homo sapiens | ENSG00000184470 | thioredoxin reductase 2 |
Leishmania braziliensis | LbrM.05.0350 | trypanothione reductase |
Leishmania donovani | LdBPK_050350.1 | trypanothione reductase |
Leishmania infantum | LinJ.05.0350 | trypanothione reductase |
Leishmania major | LmjF.05.0350 | trypanothione reductase |
Leishmania mexicana | LmxM.05.0350 | trypanothione reductase |
Loa Loa (eye worm) | LOAG_01116 | glutathione reductase |
Loa Loa (eye worm) | LOAG_02317 | thioredoxin reductase |
Mus musculus | ENSMUSG00000031584 | glutathione reductase |
Mus musculus | ENSMUSG00000075704 | thioredoxin reductase 2 |
Mus musculus | ENSMUSG00000020250 | thioredoxin reductase 1 |
Mus musculus | ENSMUSG00000000811 | thioredoxin reductase 3 |
Mycobacterium tuberculosis | Rv2855 | NADPH-dependent mycothiol reductase Mtr |
Neospora caninum | NCLIV_053860 | MGC84926 protein, related |
Neospora caninum | NCLIV_063590 | Glutathione reductase, related |
Oryza sativa | 9270365 | Os10g0415112 |
Oryza sativa | 4331112 | Os02g0813500 |
Oryza sativa | 4348623 | Os10g0415300 |
Oryza sativa | 4331719 | Os03g0163300 |
Plasmodium berghei | PBANKA_0824700 | thioredoxin reductase, putative |
Plasmodium berghei | PBANKA_1023400 | glutathione reductase, putative |
Plasmodium falciparum | PF3D7_0923800 | thioredoxin reductase |
Plasmodium falciparum | PF3D7_1419800 | glutathione reductase |
Plasmodium knowlesi | PKNH_0721800 | thioredoxin reductase, putative |
Plasmodium knowlesi | PKNH_1338200 | glutathione reductase, putative |
Plasmodium vivax | PVX_099600 | thioredoxin reductase, putative |
Plasmodium vivax | PVX_085490 | glutathione reductase, putative |
Plasmodium yoelii | PY01204 | glutathione reductase |
Plasmodium yoelii | PY02397 | thioredoxin reductase |
Saccharomyces cerevisiae | YPL091W | glutathione-disulfide reductase GLR1 |
Schistosoma japonicum | Sjp_0021180 | ko:K00384 thioredoxin reductase (NADPH) [EC1.8.1.9], putative |
Schmidtea mediterranea | mk4.000203.07 | Probable glutathione reductase 2 |
Schmidtea mediterranea | mk4.000203.06 | |
Schmidtea mediterranea | mk4.001663.03 | |
Trypanosoma brucei gambiense | Tbg972.10.12680 | trypanothione reductase, putative |
Trypanosoma brucei | Tb927.10.10390 | trypanothione reductase |
Trypanosoma congolense | TcIL3000_10_8870 | trypanothione reductase, putative |
Trypanosoma cruzi | TcCLB.503555.30 | trypanothione reductase, putative |
Toxoplasma gondii | TGME49_309730 | thioredoxin reductase |
Theileria parva | TP03_0110 | thioredoxin reductase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu2902 | Mycobacterium tuberculosis | essential | nmpdr |
Tb927.10.10390 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.10390 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.10390 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.10.10390 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
b3500 | Escherichia coli | non-essential | goodall |
PBANKA_1023400 | Plasmodium berghei | Dispensable | plasmo |
TGME49_309730 | Toxoplasma gondii | Essentiality uncertain | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
catalytic activity (GO:0003824) | decreased (PATO:0000468) | inferred from specific protein inhibition (ECO:0000020) | Trypanosoma cruzi | 5658 16167 56222 501341 563988 | ||
Annotator: | millerja@u.washington.edu. | Comment: | Effect depends on catalytic action of different peroxidase systems, specifically MPO, Mb, and HRP, on PTZ yielding PTZ+- cation radicals which result in LADH inactivation.. | References: | 17017892 | |
growth (GO:0040007) | decreased (PATO:0000468) | inferred from animal model system (ECO:0000179) | Trypanosoma cruzi | 956 5658 132257 | ||
Annotator: | millerja@u.washington.edu. | Comment: | . | References: | 15194137 | |
growth (GO:0040007) | decreased (PATO:0000468) | inferred from in vitro assay (ECO:0000181) | Trypanosoma cruzi | 813 5658 26853 504139 525512 535744 561049 567662 573089 573090 | ||
Annotator: | millerja@u.washington.edu. | Comment: | Inhibition of epimastigotes; Paglini-Oliva & Rivarola 2003. Central nervous system agents used as Trypanosoma cruzi infection chemotherapy: phenothiazines and related compounds. Current Medicinal Chemistry - Anti-Infective Agents 2(4): 323-333.. | References: | ||
growth (GO:0040007) | lethal (sensu genetics) (PATO:0000718) | inferred from animal model system (ECO:0000179) | Trypanosoma cruzi | 813 561049 573089 573090 | ||
Annotator: | millerja@u.washington.edu. | Comment: | Parasites rendered non-infective in mice; Paglini-Oliva & Rivarola 2003. Central nervous system agents used as Trypanosoma cruzi infection chemotherapy: phenothiazines and related compounds. Current Medicinal Chemistry - Anti-Infective Agents 2(4): 323-333.. | References: | ||
growth (GO:0040007) | lethal (sensu genetics) (PATO:0000718) | inferred from in vitro assay (ECO:0000181) | Trypanosoma cruzi | 5658 | ||
Annotator: | millerja@u.washington.edu. | Comment: | Lethal to trypomastigotes; also verified in mice; Paglini-Oliva & Rivarola 2003. Central nervous system agents used as Trypanosoma cruzi infection chemotherapy: phenothiazines and related compounds. Current Medicinal Chemistry - Anti-Infective Agents 2(4): 323-333.. | References: | ||
catalytic activity (GO:0003824) | decreased (PATO:0000468) | inferred from enzyme inhibition (ECO:0000184) | Trypanosoma cruzi | 813 956 2432 5658 6060 9043 13969 16167 16606 36154 56222 57921 73229 503939 503941 539326 550091 558535 560601 561049 563988 573089 573806 573807 573808 573809 577897 583295 585401 912717 912718 912719 912720 912721 912722 912723 | ||
Annotator: | millerja@u.washington.edu. | Comment: | . | References: | 11328673 17439174 19296695 19747949 | |
growth (GO:0040007) | lethal (sensu genetics) (PATO:0000718) | trypomastigote (BTO:0001398) | inferred from in vitro culture assay (ECO:0000182) | Trypanosoma cruzi | 912698 | |
Annotator: | millerja@u.washington.edu. | Comment: | Compound 3 in Figure 8: J. B. Baell and G. A. Holloway, U.S. patent application 61/092029; note that the authors question whether activity of this (or other compounds studied in this paper) was actually against TR.. | References: | 19364854 | |
growth (GO:0040007) | decreased (PATO:0000468) | inferred from in vitro culture assay (ECO:0000182) | Trypanosoma cruzi | 912738 912739 912740 | ||
Annotator: | millerja@u.washington.edu. | Comment: | Compound structures in Figure 1 of referenced publication. | References: | 3135548 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.7
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Trypanosoma cruzi | trypanothione reductase, putative | 189 aa | 97.9% | 189 aa | Compounds | References |